CD8A and neoplasm: FC analysis of the tumor adaptive immune cell populations indicated that VVL-TD-RFP treatment enhanced the CD8+ T-cell population compared with VVLΔTKΔN1L and PBS treatments (figure 3C) and reduced the proportion of the Treg cells compared with VVLΔTKΔN1L treatment (figure 3G) at day 6 after the first treatment.